HC Biopharma Inc.
8
7
7
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Role: lead
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
Role: lead
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
Role: lead
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Role: lead
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Role: lead
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
Role: lead
A Study of HC006 in Subjects With Advanced Solid Tumors
Role: lead
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Role: lead
All 8 trials loaded